Cancer Predisposition Genetics Biobank, Canada

Certification Status: Approved

Registration Status: Completed

Objective: The Cancer Predisposition Genetics Biobank's purpose is the conservation of biological material and associated clinical and genetic data collected from patients with cancer, their family members as well as from control participants as required, in order to allow future research on cancer predisposition genetics. The study of predisposition factors may lead to the discovery of novel cancer predisposition genes or biomarkers that will help develop a better understanding of these diseases and better diagnostic tests.

Registered Biobank Name	Cancer Predisposition Genetics Biobank
Biobank Leader	Zoulikha Rezoug
Country	Canada
Email for biobank inquiries	zoulikha.rezoug@ladydavis.ca
Principal Investigator	Dr William D. Foulkes
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).